HighTower Advisors
SUPN icon

HighTower Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

HighTower Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
9,198
-5,612
-38% -$270K ﹤0.01% 2889
2026
Q1 		$766K Buy
14,810
+5,815
+65% +$296K ﹤0.01% 2382
2025
Q4 		$447K Buy
8,995
+2,092
+30% +$102K ﹤0.01% 2711
2025
Q3 		$330K Sell
6,903
-1,053
-13% -$42.4K ﹤0.01% 2965
2025
Q2 		$251K Sell
7,956
-678
-8% -$21.7K ﹤0.01% 3090
2025
Q1 		$283K Sell
8,634
-496
-5% -$17.6K ﹤0.01% 2912
2024
Q4 		$330K Buy
9,130
+624
+7% +$22K ﹤0.01% 2816
2024
Q3 		$264K Buy
+8,506
New +$265K ﹤0.01% 2907
2024
Q1 		– Sell
-13,708
Closed -$395K – 3984
2023
Q4 		$395K Buy
13,708
+1,231
+10% +$32.6K ﹤0.01% 2498
2023
Q3 		$341K Buy
+12,477
New +$380K ﹤0.01% 2495
2023
Q2 		– Sell
-5,962
Closed -$221K – 3679
2023
Q1 		$221K Sell
5,962
-1,270
-18% -$48.8K ﹤0.01% 2681
2022
Q4 		$263K Buy
+7,232
New +$251K ﹤0.01% 2568
2020
Q3 		– Sell
-51,379
Closed -$1.22M – 2690
2020
Q2 		$1.22M Buy
+51,379
New +$1.14M 0.01% 1028
2018
Q4 		– Sell
-4,035
Closed -$203K – 2356
2018
Q3 		$203K Sell
4,035
-190
-4% -$9.38K ﹤0.01% 1951
2018
Q2 		$252K Buy
+4,225
New +$219K ﹤0.01% 1784
2016
Q4 		– Sell
-18,761
Closed -$464K – 2030
2016
Q3 		$464K Buy
+18,761
New +$425K 0.01% 1277
2016
Q2 		– Sell
-20,207
Closed -$306K – 2008
2016
Q1 		$306K Sell
20,207
-1,475
-7% -$19.2K ﹤0.01% 1596
2015
Q4 		$295K Buy
+21,682
New +$335K ﹤0.01% 1581

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

HighTower Advisors's SUPN Position: Q2 2026 in Review

HighTower Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 38% in Q2 2026, selling an estimated $270K and leaving 9,198 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #2889.

HighTower Advisors first reported a position in SUPN in Q4 2015 and has held it in 18 quarters since. The position peaked at $1.22M in Q2 2020. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • HighTower Advisors held 9,198 shares of Supernus Pharmaceuticals worth $428K as of Q2 2026.
  • HighTower Advisors sold 5,612 Supernus Pharmaceuticals shares in Q2 2026, an estimated $270K.
  • Supernus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2889 holding.
  • HighTower Advisors first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 18 quarters since.
  • HighTower Advisors's Supernus Pharmaceuticals position peaked at $1.22M in Q2 2020.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.